Navigation Links
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Date:12/13/2007

tistically significant, progressive and dose-dependent weight loss over a 12-week period. Lorcaserin was generally well tolerated at all doses and had no apparent effects on heart valves or pulmonary artery pressure. A scheduled review by an independent Echocardiographic Safety Monitoring Board of unblinded echocardiograms performed after patients completed six months of dosing in the BLOOM trial confirmed that differences, if any, in the rates of FDA-defined valvulopathy in patients treated with lorcaserin and in the control group did not meet the board's predetermined stopping criteria.

About Obesity

Obesity affects tens of millions of people in the United States and poses a serious long-term threat to their health and welfare. The number of overweight and obese people has substantially increased over the past several decades. Approximately two-thirds of all adults in the United States are obese or overweight, and medical and related costs of obesity were more than $123 billion according to a 2005 report by the International Diabetes Federation. Being obese or overweight is associated with increased risk of a number of conditions, including heart disease, stroke, diabetes, cancer and osteoarthritis. Medical treatment options for obese and overweight people currently are limited.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmace
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
(Date:7/1/2015)... Calif. , July 1, 2015   ... on the development of groundbreaking drugs to treat ... announced today that Robert G. Miller , ... at Sutter Health,s California Pacific Medical Center in San ... ALS Association for $1.5 million to help fund ...
(Date:7/1/2015)... -- InferMed , s ... will augment ... olutions suite   Elsevier , a ... services, announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the ...
(Date:6/30/2015)... KYOTO, Japan , July 1, 2015 R-Japan ... Act on the Safety of Regenerative Medicine from the Ministry ... Welfare on June 29, 2015. The fact ... cell processing facility through the auditing from Pharmaceuticals and Medical ... filing the application, allows it to provide stem cell manufacturing ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... Sheets: NNLX) NanoLogix personnel will display the company,s BNP(TM) ... ASM Meeting to be held at the Pennsylvania Convention ... meeting is the world,s premier event for microbiology development. ... Bret Barnhizer. Exhibition information can be found at ...
... 5 Cadient Interactive , a ... custom-created digital campaigns, tools and services, today announced that ... team appointing Bethany (Beth) Hartzell to associate creative director. ... experts and digital thought leaders to provide unique and ...
... Consulting Corporation , an IT consulting and software ... SharePoint applications , announced today that it has ... biopharmaceutical company in the Boston area. The engagement ... data from a SharePoint 2003 environment to the Microsoft ...
Cached Biology Technology:NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents 2NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents 3Cadient Interactive Expands Creative Leadership with New Associate Director 2Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... products, and in particular, wholegrain products, are important ... components which are beneficial for human health. Analysis ... the HEALTHGRAIN project of the European Union has ... content and composition of these components. Furthermore, a ...
... level of dietary protein are less likely to suffer ... is less, according to a new study by the ... an affiliate of Harvard Medical School. The study, which ... the Framingham Osteoporosis Study, found that individuals who were ...
... biologists has found that existing diversity in some coral ... disturbances such as those predicted from climate warming. ... species of algae living within corals may determine which ... The results will be published online in the ...
Cached Biology News:Dietary protein may reduce hip fractures in the elderly 2New study sheds light on corals' susceptibility to temperature change 2
... Purification Kit, 25 purifications. Allows ... probesProvides efficient removal of unincorporated CyDye ... with superior yields of labeled cDNA ... of cDNA labeled by either direct ...
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Apoptosis Detection Systems and Reagents...
Biology Products: